It is used as a second line treatment to manage symptoms of rheumatoid arthritis after treatment with a disease-modifying antirheumatic drug (DMARD) has failed. It can be used in combination with some DMARDs. It is used to people with a cryopyrin-associated periodic syndrome, including neonatal-onset multisystem inflammatory disease. It is used to treat Schnitzler's syndrome (off label in the US). Off label, it is used to treat systemic juvenile idiopathic arthritis (SJIA), gout, calcium pyrophosphate deposition (CPPD), Behcet’s Disease, ankylosing spondylitis, uveitis, and other auto-inflammatory syndromes. In December 2021, the European Medicines Agency authorized the use of<unk>  "to treat COVID-19 in adults with pneumonia requiring supplemental oxygen (low or high flow oxygen) and who are at risk of developing severe respiratory failure, as determined by blood levels of a protein called suPAR (soluble urokinase plasminogen activator receptor) of at least 6 ng per ml." +Approvals Condition Country RA CAPS FMF AOSD Schnitzler's MKD TRAPS DIRA HLH US 2001 2020 UK 2018 2018 2018 2018 2021 EU 2002 2002 2002 Russia 2021
Anakinra
Canakinumab
Sarilumab
Crofelemer
Tofacitinib
Ecallantide
Emapalumab
Anifrolumab